Biotech Values

[DewDiligence]

…even Teva talked about 25% or so [market share for thrice-weekly C]

What’s your own forecast?

I think the market-share ceiling is 15-20%, which is at least in the same zip code with Teva’s number, but is well below the outsized numbers from some of the sell-side analysts.